Retatrutide vs Mazdutide
Triple agonist vs dual GLP-1/glucagon.
| Attribute | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) | Mazdutide IBI362, GLP-1/Glucagon dual agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Triple-receptor metabolic research | GLP-1/glucagon dual agonist weight-loss research |
| In plain English | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. | GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone. |
| How it works | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. | Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis). |
| Researchers study | Obesity, hepatic steatosis, and metabolic syndrome. | Obesity and metabolic-associated liver disease, particularly in Chinese clinical research. |
| Internet discussion | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide. | Discussed alongside survodutide and retatrutide in next-gen metabolic research. |
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.
Mazdutide
GLP-1/glucagon dual agonist weight-loss research
GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone.
Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
Obesity and metabolic-associated liver disease, particularly in Chinese clinical research.
Discussed alongside survodutide and retatrutide in next-gen metabolic research.
Mazdutide is a GLP-1/glucagon dual agonist researched for obesity and metabolic disease.